Pilot Study Evaluating the Impact of Stress Reduction on Atherosclerotic : Heart and Mind Study

Sponsor
Massachusetts General Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT04496947
Collaborator
(none)
30
1
2
72
0.4

Study Details

Study Description

Brief Summary

The plot study aims to evaluate the effect of 8 weeks of stress reducing intervention on atherosclerotic plaque inflammation in adults, as quantified by positron emission tomography (PET) with fluorine-2-deoxy-D-glucose (FDG) in individuals with increased psychosocial stress.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Stress Reduction
N/A

Detailed Description

This randomized controlled imaging study will be performed to evaluate the impact of mindfulness-based stress reduction via a mind body program on arterial inflammation in individuals with self-identified high levels of stress. Individuals will undergo baseline Fluorodeoxyglucose-Positron emission tomography / magnetic resonance imaging and will then be randomized to the stress-reduction intervention group or no intervention groups by blocks of 2:1, with stratification by age and sex. The stress reduction sessions focus on developing an understanding of stress physiology and the physiology of the relaxation response, on developing a regular practice of eliciting the relaxation response, and on learning cognitive behavioral and positive psychology/resilience skills.

During the screening period, patient acceptability for the study will be assessed based on medical history, concomitant medications, physical examination, and clinical laboratory test results. Acceptability for study participation will be confirmed for subjects who identify as having increased levels of stress and/or a Perceived Stress Scale score >5. Once the patient has passed screening, they will undergo baseline imaging followed by randomization and group assignment. Approximately 12 weeks after randomization, all individuals will return for follow-up imaging and evaluation.

Thus, 2 Fluorodeoxyglucose-Positron emission tomography / magnetic resonance imaging scans will be performed throughout the study for baseline and follow up to assess the intervention's impact on the brain and arterial inflammation, along with changes in related positron emission tomography / magnetic resonance imaging imaging parameters. Perceived Stress Scale will be delivered prior to Fluorodeoxyglucose-Positron emission tomography / magnetic resonance imaging, during both imaging visits to measure perceived psychological stress. During both imaging sessions, subjects will be exposed to overt faces to measure signals during brain imaging.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
30 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
2 groups: stress reduction intervention no intervention2 groups: stress reduction intervention no intervention
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Other
Official Title:
Pilot Study Evaluating the Impact of Stress Reduction on Atherosclerotic : Heart and Mind Study
Actual Study Start Date :
Sep 1, 2018
Anticipated Primary Completion Date :
Aug 31, 2023
Anticipated Study Completion Date :
Aug 30, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Stress Reduction

8 week stress reduction course

Behavioral: Stress Reduction
The stress reduction program is a multimodal mind-body resiliency program that incorporates 3 core components into each session: Elicitation of the Relaxation Response (RR) through mind-body techniques; Discussion about stress awareness to learn how to identify personal stressors and experiences of stress; and Coping strategies and adaptive perspective-taking to promote positive well-being.

No Intervention: Control

No intervention

Outcome Measures

Primary Outcome Measures

  1. Change in arterial inflammation by PET [2 months]

    Change in arterial inflammation based on FDG PET - from initial imaging to repeat imaging.

Eligibility Criteria

Criteria

Ages Eligible for Study:
30 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • • Aged between 30-65 years

  • Identifies as having increased levels of stress and/or has a Perceived Stress Scale (PSS) score >5 at baseline, and is interested in participating

Exclusion Criteria:
  • Perceived Stress Scale (PSS) score <6

Contacts and Locations

Locations

Site City State Country Postal Code
1 Massachusetts General Hospital Boston Massachusetts United States 02114

Sponsors and Collaborators

  • Massachusetts General Hospital

Investigators

  • Principal Investigator: Ahmed Tawakol, MD, MGH

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Ahmed Tawakol, Director, Nuclear Cardiology, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT04496947
Other Study ID Numbers:
  • 2017P000706
First Posted:
Aug 4, 2020
Last Update Posted:
Apr 19, 2022
Last Verified:
Apr 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 19, 2022